基因组测序技术公司10x Genomics, Inc.（NYSE: TXG）今日盘前股价大涨5.10%，主要受益于公司发布的季度财报优于市场预期。
根据公司公布的最新财报，截至2025年3月31日的季度，10x Genomics调整后每股亏损为0.36美元，明显好于分析师平均预期的0.47美元亏损。公司营收同比增长9.8%，达到1.5488亿美元，同样超过了分析师预期的1.3245亿美元。这一业绩表现显示出公司在面对挑战时仍保持了良好的增长势头。
尽管10x Genomics在过去一个季度股价下跌了4.8%，今年迄今为止更是累计下跌了42.1%，但此次超预期的财报结果似乎重新点燃了投资者的信心。值得注意的是，华尔街分析师对该公司的看法仍然谨慎，目前对10x Genomics的平均评级为"持有"，12个月目标价中位数为14.50美元。在当前市场环境下，投资者可能需要密切关注公司未来的业绩表现和行业发展趋势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.